

March 20, 2019



# Kane Biotech Schedules Full Year 2018 Earnings Conference Call and Business Update

## Conference Call to be held Tuesday, March 26 at 4:00pm ET

WINNIPEG, Manitoba, March 20, 2019 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE), (the "Corporation" or "Kane Biotech"), is pleased to announce today that it will host a conference call and webcast on Tuesday, March 26, 2019 at 4:00pm Eastern Time to discuss its financial results for the fourth quarter and full year 2018, in conjunction with the filing of its annual Year End Financial Statements for the fourth quarter and full year ended December 31, 2018.

Marc Edwards, Chief Executive Officer and Ray Dupuis, Chief Financial Officer of Kane Biotech, will host the call and provide an update on the Company's business strategy including product developments, licensing and business development and other initiatives in progress. There will be an opportunity for participants dialed-in via conference call to ask questions to management in a Q&A session taking place following his prepared remarks. To participate in the call, please dial 1-877-268-9044 (toll-free) in the U.S. and Canada. The conference ID number for both the call and webcast is 6958649.

<b>Event:</b>	Kane Biotech Investor Update
<b>Date:</b>	Tuesday, March 26, 2019
<b>Time:</b>	4:00pm (Eastern Time)
<b>Participant Dial-in:</b>	1-877-268-9044 (toll free)
<b>Conference ID:</b>	6958649
<b>Webcast Link:</b>	<a href="https://edge.media-server.com/m6/p/yfay2q7s">https://edge.media-server.com/m6/p/yfay2q7s</a>

A live and archived audio webcast of the conference call will also be available on the investor relations page of Kane Biotech's corporate website at [www.kanebiotech.com](http://www.kanebiotech.com).

### About Kane Biotech

Kane Biotech is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The Corporation has a portfolio of biotechnologies, intellectual property (66 patents and patents pending, trade secrets and trademarks) and products developed by the Corporation's own biofilm research expertise and acquired from leading research institutions. StrixNB(TM), DispersinB(R), Aledex(R), bluestem(TM), AloSera(TM), coactiv+(TM) and Kane(R) are trademarks of Kane Biotech Inc. The Corporation is listed on the TSX Venture Exchange under the symbol "KNE".

For more information, please visit [www.kanebiotech.com](http://www.kanebiotech.com) or contact:

Marc Edwards

Chief Executive Officer

Kane Biotech Inc.

+1 (514) 910-6991

[medwards@kanebiotech.com](mailto:medwards@kanebiotech.com)

Grant Humphrey

Vice President, Sales and Business Development

Kane Biotech Inc.

+1 (204) 914-5089

[ghumphrey@kanebiotech.com](mailto:ghumphrey@kanebiotech.com)

Joe Green

US. Investor Relations

Edison Inc.

+1 (646) 653-7030

[jgreen@edisongroup.com](mailto:jgreen@edisongroup.com)

*Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.*

### **Caution Regarding Forward-Looking Information**

*This press release contains certain statements regarding Kane Biotech Inc. that constitute forward-looking information under applicable securities law. These statements reflect management's current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. These risks and uncertainties include, but are not limited to, risks relating to the Company's: (a) financial condition, including lack of significant revenues to date and reliance on equity and other financing; (b) business, including its early stage of development, government regulation, market acceptance for its products, rapid technological change and dependence on key personnel; (c) intellectual property including the ability of the Company to protect its intellectual property and dependence on its strategic partners; and (d) capital structure, including its lack of dividends on its common shares, volatility of the market price of its common shares and public company costs. Further information about these and other risks and uncertainties can be found in the disclosure documents filed by the Company with applicable securities regulatory authorities, available at [www.sedar.com](http://www.sedar.com). The Company cautions that the foregoing list of factors that may affect future results is not exhaustive.*



Source: Kane Biotech Inc.